Retrospective 10-year follow-up of the HIDIT-II trial in hepatitis D (107 patients who completed 96 weeks' therapy): liver-related endpoints were less frequent after PEG-IFNα-2a plus tenofovir than PEG-IFNα-2a alone (14% vs 34%, p=0.02).
RCTn = 107
Yurdaydin et al. Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy